We assessed serum and exosomal BATF2 expressions in NPC patients at baseline (newly diagnosed), after receiving clinical treatments (radiotherapy and/or chemotherapy and/or targeted therapy), and suffering recurrence. The gene discussed is BATF2; the disease is nasopharyngeal carcinoma.